Press Releases

November 22, 2019

Bethesda, MD, November 22, 2019 - The Accelerating Medicines Partnership (AMP) program for Parkinson’s disease (PD) has launched a data portal to provide de-identified information collected from 4,298 PD patients and healthy controls to researchers working to develop effective therapies for the disease. The portal enables researchers to study complex data sets and perform genome-wide analyses at a scale previously impossible.

November 14, 2019

The Foundation for the National Institutes of Health (FNIH) and the Friends of Patients at the NIH (Friends) are launching a new collaboration called “Partnership for Patients” to leverage one another’s competence and infrastructure to ensure that patients in need at the NIH Clinical Center receive support to participate in groundbreaking and potentially life-saving treatments.

October 24, 2019

The Foundation for the National Institutes of Health (FNIH) bestowed the 2nd annual Trailblazer Prize for Clinician-Scientists (Trailblazer Prize) to James Kochenderfer, M.D., of the National Cancer Institute (NCI), at the FNIH Annual Fall Board Dinner. Dr. Kochenderfer received the Trailblazer Prize and a $10,000 honorarium for pioneering the development of immunotherapies that leverage chimeric antigen receptor (CAR) T-cells to treat blood cancers. The Trailblazer Prize is made possible by a generous donation from John I. Gallin, M.D., and Elaine Gallin, Ph.D., to the FNIH.

October 24, 2019

The Board of Directors of the Foundation for the National Institutes of Health (FNIH) has elected lawyer and business leader Julie Bell Lindsay as its newest member. The FNIH Board elected Ms. Lindsay on May 23, 2019 and her appointment took effect on October 24, 2019.

September 18, 2019

The Foundation for the National Institutes of Health (FNIH) has named the Doris Duke Charitable Foundation (DDCF) and Jane Sayer, Ph.D., the recipients of the 2019 Charles A. Sanders, M.D., Partnership Award. Now in its fourth year, this award recognizes persons and/or organizations that have made significant contributions to the FNIH’s work to build, implement and nurture public-private partnerships in support of the mission of the National Institutes of Health (NIH).

September 4, 2019

The Foundation for the National Institutes of Health (FNIH) has selected the finalists of the 2nd annual Trailblazer Prize for Clinician-Scientists (Trailblazer Prize): Ami S. Bhatt, M.D., Ph.D., Stanford University, James Kochenderfer, M.D., National Cancer Institute (NCI), Evan Macosko, M.D., Ph.D., Broad Institute and Giovanni Traverso, M.B., B.Chir, Ph.D., Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital, Harvard Medical School.

April 3, 2019

The Foundation for the National Institutes of Health (FNIH) is delighted to name Yasmine Belkaid, Ph.D., the winner of the 2019 Lurie Prize in Biomedical Sciences for blazing a trail in understanding the microbiome’s significant role in immune regulation. The human body houses trillions of microscopic organisms called microbes (i.e. bacteria, fungi and viruses) that collectively make up a microbiome. While many of these microbes are beneficial to health (commensal), others can be harmful (pathogenic). Dr. Belkaid revolutionized our understanding of the role of these microbes in the gut and skin, demonstrating that they are essential for triggering an immune response to help fight infection, but that they also can initiate inflammatory disease. The Lurie Prize in Biomedical Sciences will be presented to Dr. Belkaid at the FNIH Award Ceremony on May 22, 2019 in Washington, D.C.

January 29, 2019

The Lung Cancer Master Protocol (Lung-MAP), the first precision medicine trial in lung cancer supported by the National Cancer Institute (NCI), part of the National Institutes of Health, is undergoing a major expansion to include patients with all non-small cell lung cancers – which make up about 85 percent of all lung cancer diagnoses in the U.S.

January 2, 2019

The Board of Directors of the Foundation for the National Institutes of Health (FNIH) welcomes distinguished scientific leader Elias Zerhouni, M.D., as its latest member. The FNIH Board of Directors elected Dr. Zerhouni in May 17, 2018 and his appointment takes effect on January 1, 2019.

October 25, 2018

The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) and the Critical Path Institute (C-Path) Predictive Safety Testing Consortium (PSTC) have received the first ever qualification of a clinical safety biomarker awarded by the U.S. Food and Drug Administration (FDA) –a major milestone that will improve the detection of drug-induced kidney injury in early phase drug development. The newly qualified biomarker can now be used in Phase I clinical trials to aid in the detection of acute kidney tubular injury in healthy volunteers. This will help improve the development of safe and effective medicines where concern has been raised that an investigational drug may cause kidney injury.